The Fatty Acid Biosynthesis Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Fatty Acid Biosynthesis Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fatty Acid Biosynthesis Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fatty Acid Biosynthesis Disorders and features dormant and discontinued products.
GlobalData tracks 35 drugs in development for Fatty Acid Biosynthesis Disorders by 31 companies/universities/institutes. The top development phase for Fatty Acid Biosynthesis Disorders is preclinical with 16 drugs in that stage. The Fatty Acid Biosynthesis Disorders pipeline has 28 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Fatty Acid Biosynthesis Disorders pipeline products market are: Poxel, Polaryx Therapeutics and Orphi Therapeutics.
The key targets in the Fatty Acid Biosynthesis Disorders pipeline products market include Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80), Beta-Hexosaminidase Subunit Alpha (Beta-N-Acetylhexosaminidase Subunit Alpha or N-Acetyl-Beta-Glucosaminidase Subunit Alpha or HEXA or EC 3.2.1.52), and Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB).
See Also:
The key mechanisms of action in the Fatty Acid Biosynthesis Disorders pipeline product include Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Inhibitor with three drugs in Phase III. The Fatty Acid Biosynthesis Disorders pipeline products include seven routes of administration with the top ROA being Oral and seven key molecule types in the Fatty Acid Biosynthesis Disorders pipeline products market including Small Molecule, and Gene Therapy.
Fatty Acid Biosynthesis Disorders overview
Fatty acid biosynthesis disorders (FABDs) are a group of inherited metabolic disorders that affect the ability of the body to use fatty acids as a source of energy. Fatty acids are long chains of carbon and hydrogen atoms that are stored in fat cells and can be broken down to produce energy when glucose (sugar) is not available. However, people with FABDs have defects in the enzymes or transport proteins that are involved in the process of fatty acid breakdown, also called fatty acid oxidation. This leads to a buildup of fatty acids or their byproducts in the blood and tissues, and a shortage of energy for the cells. FABDs can cause various symptoms depending on the type and severity of the disorder, such as low blood sugar, muscle weakness, heart problems, liver enlargement, brain damage, and developmental delays. FABDs are diagnosed by newborn screening tests, genetic tests, or biochemical tests that measure the levels of fatty acids or their metabolites in the blood or urine. Treatment of FABDs depends on the specific disorder, but usually involves dietary modifications, supplements, medications, and avoiding fasting or prolonged exercise. FABDs are rare disorders that affect about 1 in 10,000 to 50,000 people worldwide.
For a complete picture of Fatty Acid Biosynthesis Disorders’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
